ctCTLA4 Pharmaceutical compositions for preventing and treating of inflammatory respiratory diseases comprising fusion protein of cell penetrating peptide and ctCTLA4 peptide

摘要

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory respiratory disease having a fusion protein, in which a cell permeable peptide and a ctCTLA4 peptide are fused, as an active component. Through a method of administration via a respiratory system, which has not been able to achieve an effective treatment and prevention effect in the past, the present invention has remarkably outstanding permeability and delivery efficiency to bronchial and pulmonary cells, and also exhibits remarkably improved activity of suppressing cytokine expression, suppressing airway inflammation, alleviating hypersensitive responses of the airway to allergens, and alleviating Th2 inflammation, etc., compared to conventional therapeutic agents for inflammatory respiratory diseases, especially, allergic asthma. Therefore, the present invention can obtain a prompt, rapid, and efficient therapeutic or prophylactic effect.